Christopher C Corless

This inventor holds 3 USPTO granted patents. Top assignees: Dana-Farber-Cancer Institute Inc., Oregon Health & Science University, The Brigham and Women's Hospital, Inc.. Active years: 2009-2012.

USPTO Granted Patents = 3

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 3(Granted Patents)

Company Filing History:

3 out of 1,264

Dana-Farber-Cancer Institute Inc.

patents

3 out of 524

Oregon Health & Science University

patents

3 out of 1,422

The Brigham and Women's Hospital, Inc.

patents

4. 2 out of 953

The United States Government as Represented by the Department of Veterans Affairs

patents

where one patent can have more than one assignee

Years Active: 2009-2012

Loading Chart...

3 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8202969 - Platelet derived growth factor receptor alpha (PDGFRA) polypeptides comprising activating mutation(s) (2012-06-19),

2. 7875710 - Nucleic acids encoding platelet derived growth factor receptor alpha (PDGFRA) activating mutations (2011-01-25),

3. 7595154 - Method of detecting a neoplasia associated with an activating platelet derived growth factor receptor alpha (PDGFRA) mutation (2009-09-29),

Title: Christopher C Corless: Innovator in Cancer Research

Introduction

Christopher C Corless is a notable inventor based in Portland, OR (US). He has made significant contributions to the field of cancer research, particularly through his innovative work on platelet-derived growth factor receptor alpha (PDGFRA) polypeptides. With a total of 3 patents, his research has the potential to impact diagnosis and treatment options for cancer patients.

Latest Patents

Corless's latest patents focus on the development of tyrosine kinase protein and nucleic acid variants, specifically PDGFRA variants. These activating forms of PDGFRA are linked to neoplasms and the progression of cancer. His disclosures provide methods for diagnosis and prognosis, as well as the development of new therapeutic agents utilizing these molecules and their fragments. Additionally, he has developed kits for employing these methods and compositions, further enhancing the potential for clinical applications.

Career Highlights

Throughout his career, Christopher C Corless has worked with prestigious institutions such as Brigham and Women's Hospital, Inc. and Dana-Farber Cancer Institute Inc. His work in these organizations has allowed him to collaborate with leading experts in the field, contributing to advancements in cancer research and treatment.

Collaborations

Some of his notable coworkers include Jonathan A Fletcher and Michael C Heinrich. Their collaborative efforts have further enriched the research landscape in which Corless operates.

Conclusion

Christopher C Corless stands out as an influential inventor in the realm of cancer research. His innovative patents and collaborations have the potential to lead to significant advancements in the diagnosis and treatment of cancer.